

# Request title: Multiple Myeloma Patients

---

Date of Response: 22<sup>nd</sup> October 2015

Further to your Freedom of Information request, the Trust has answered your questions in the order they appear in your request.

## Request and reply

### Section 1 – Treatment and Management

1. How many patients has your Trust diagnosed with multiple myeloma in the calendar year 2014?  
There were 46 in total.
2. How many multiple myeloma patients in your Trust received systemic anti-cancer treatment in the calendar year 2014?  
There were 176 in total.
3. How many patients aged 75 years and over has your Trust diagnosed with multiple myeloma in the calendar year 2014?  
There were 15 in total.
4. How many multiple myeloma patients aged 75 years and over in your Trust received systemic anti-cancer treatment in the calendar year 2014?  
There were 74 in total.
5. Does your Trust produce local guidelines to support the management of elderly cancer patients?  
No.
6. Does your Trust produce local guidelines to support the management of elderly multiple myeloma patients?  
No.

(Note: Multiple Myeloma is defined by the ICD-10 code as C90.0 - C90.3)

### Section 2 – Specialist Geriatric Input

7. Does your Trust's multiple myeloma multidisciplinary team (MM MDT) include input from a geriatrician?  
A geriatrician is not a core member of the Haematology MDT.
  - a. If so, does a geriatrician routinely attend all MM MDT meetings?  
No.
  - b. How often does the MM MDT meet?  
Once a week on a Wednesday for a 2 hourly meeting.
8. Do multiple myeloma patients aged 75 and over at diagnosis routinely receive a consultation with a geriatrician?  
Not routinely but a referral would always be promptly made if it was clinically required.
  - a. If so, does this happen prior to making a decision as to whether a patient is suitable for systemic anticancer therapy?  
See above.

b. If, so does information from this consultation feed into clinical decision making?  
If referred to a geriatrician or any other speciality all supporting clinical information is fed into clinical decision making.

9. How frequently do all multiple myeloma patients aged 75 years and over receive a consultation with a geriatrician?

As the clinical need requires.

a. How is this information used in these consultations fed into clinical management and decision making?

If the clinical need requires a referral to a geriatrician, then information from the consultation may be fed back to the Clinical Nurse Specialist or Consultant either verbally, electronically or via the Clinical Document Management System.

### Section 3 – Specific Tools and Metrics

10. Does your Trust use Comprehensive Geriatric Assessment to assess if a patient with cancer is suitable for treatment?

No.

a. If so, what proportion of multiple myeloma patients aged 75 and over received the assessment in 2014?

Not applicable.

b. Who routinely carries out this assessment (i.e. a nurse or a consultant – and what type of consultant (haematologist or geriatric))?

Not applicable.

11. Does your Trust routinely assess patients over the age of 75 according to a Comorbidity Score (either a standardised score such as the Charlson index or a local 'in house' score, please specify)?

No.

a. If so, what proportion of multiple myeloma patients aged 75 and over received the assessment in 2014?

Not applicable.

b. Who routinely carries out this assessment (i.e. a nurse or a consultant - and what type of consultant (haematologist or geriatric))?

Not applicable.

12. Does your Trust routinely assess patients over the age of 75 according to a Clinical Frailty Scale (either a standardised scale or a local 'in house' scale, please specify)?

No.

a. If so, what proportion of multiple myeloma patients aged 75 and over received the assessment in 2014?

Not applicable.

b. Who routinely carries out this assessment (i.e. a nurse or a consultant - and what type of consultant (haematologist or geriatric))?

Not applicable.